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Fluorescence in situ hybridization (FISH) with centromere 
probes was used to investigate numerical aberrations of chromosomes 
1, 7, 8, 10, 18, and Y in 46 prostate carcinoma (PC) and 11 benign 
prostatic hyperplasia (BPH) samples. None of the benign specimens 
showed any chromosomal aberration. Forty-one of 46 PC specimens 
showed numerical aberrations of one or more chromosomes. All in- 
vestigated chromosomes howed numerical aberrations in at least 
30% of the specimens, gain being more frequent than loss. Compari- 
son of DNA flow cytometry (FCM) and FISH results showed that 
not only aneuploid tumors but also most diploid tumors harbored 
numerical chromosome aberrations. Chromosome 10 was the most 
frequently gained (65%), and Y the most frequently lost chromosome 
(14%). Nonmetastatic and metastatic tumors differed significantly (P 
< .05) in the number of copies for chromosomes 7, 8, and 10, but 
not for 1, 18, and Y. These results suggest slrongly that gains of 
chromosomes 7, 8, and 10 are involved in PC progression. HUM 
PA'I~-IOL 27:720--727. Copyright © 1996 by W.B. Saunders Company 
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Abbreviations: FISH, fluorescence in situ hybridization; PC, pros- 
tate carcinoma; BPH, benign prostatic ~vperplasia; TUR, transure- 
thral resection; PBS, phosphate-buffered saline; FCM, flow cytome- 
try; ANC, average number of copies; LOH, loss of heterozygosity; 
LM, lymph node metastasis. 
By cytogenetic analysis, structural and numerical 
aberrations of chromosomes 1, 7, 8, 10, 16, and Y~ were 
identified in about 25% of the prostate carcinomas 
(PCs) studied. However, this figure is probably an un- 
derestimation f the true extent of the aberrations. This 
is because of selective isolation and preferential in vitro 
growth of nonmalignant prostate pithel iumY The use 
of interphase cytogenetic techniques for characteriza- 
tion of uncultured PC material has been stimulated by 
these findings. Application of in situ hybridization with 
centromere-specific DNA probes to fixed sections of PC 
has shown numerical aberrations for chromosomes 1,
7, 8, 10, 12, 17, 18, X, and y4~7 The finding of numerical 
aberrations in different chromosomes is not surprising 
because about 50% of the PCs have an aneuploid DNA 
content. 8 In the present study, the authors investigated 
numerical changes of chromosomes 1, 7, 8, 10, 18, and 
Y using fluorescence in situ hybridization (FISH) with 
centromere-specific DNA probes on nuclear suspen- 
sions of fresh tissue samples from 11 benign prostatic 
hyperplasia (BPH) and 43 PC patients. Selection of this 
chromosome panel was based on evidence from the 
literature and previous studies 9-a2 that these chromo- 
somes were possibly implicated in PC development or 
progression. Study of recurring patterns of specific 
chromosomal berrations might provide new informa- 
tion about the genetic events involved in these pro- 
cesses. 
The BPH specimens howed no deviation from 
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normal diploidy, so consequently the BPH results were 
used as a control. Based on this, significant chromo- 
some gains and losses in the PC samples could be ana- 
lyzed. Possible correlations with clinical parameters and 
ploidy as determined by DNA flow cytometry (FCM) 
were investigated. 
MATERIALS AND METHODS 
Tumor Tissues 
Eleven BPH specimens were studied, after being ob- 
tained at transurethral resection (TUR) or prostatectomy for
BPH. The mean age of the BPH patients was 72.4 _+ 5.6 
(range, 64 to 80 years). Forty-six PC specimens, from 43 differ- 
ent patients were studied, obtained, and studied at radical 
prostatectomy (15 specimens), TUR (26 specimens), orpelvic 
lymph node dissection (five specimens). From one lymph 
node specimen (PC295), a cell line emerged after xeno- 
grafting on nude mice. Tissue from this cell line at mouse 
passage was used instead of the original tissue. The mean age 
of the PC patients was 66.7 + 10.5 (range, 49 to 93 years). 
The percentage of tumor cells present in the tissue specimens 
was assessed from paraffin sections of adjacent tissue. Only 
specimens with more than 50% tumor cells were included in 
the study. 
From 23 patients, detailed clinical data could be obtained 
(Table 1). Twelve patients were lymph node negative (non- 
metastatic), and 11 were node positive (metastatic) atthe time 
of first surgery. Three patients had organ-confined disease 
(T2N0), whereas four tumors showed periprostatic spread 
(T4). The remaining 16 patients howed extracapsular exten- 
sion of the tumor (T3N0) or had positive lymph nodes (N+, 
TNM system for PC 199213). Three of these tumors were well 
differentiated (G1, all from primary tumors obtained at radi- 
cal prostatectomy); 10were moderately differentiated (G2); 
and in 10, poorly differentiated (G3) areas were found. From 
three patients (case nos. 4, 5, and 10), two consecutive tumor 
samples were obtained. The second sample of case no. 4 was 
obtained from a local recurrence, diagnosed 37 months after 
radical prostatectomy. 
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TA6LE 1. Detailed Clinical Data, FCM, and FISH Results From 21 Patients 
PC TNM at 
Case No. NR Tissue G Surgery FU* Status FCM Aneusomies t 
1 202 TUR 2 T4N3M0 52 (44) D A P1, P7, P8, P10, P18 
M1, M7, M8, M10 
2 236 LM 3 T3N2M0 50 (0) DN D P10 
3 244 LM 2 T2N2M0 56 (0) D A P7, P8, P10, P18 
4 256 P 2 T3N1M0 53 (37) P T P8, P10, P18 
M8, M10, M18 
384 TUR T P1, P7, P8, P10, P18 
M7 
5 269 LM 3 T3NxM0 15 (0) D AH P1, P7, P8, P10, P18 
291 TUR A P1, P8, P10, P18 
M10 
6 270 LM 3 TONxM2 17 (0) D T P1, PT, P8, P10, P18, PY 
7 288 P 2 T3NOM0 40 NP D P1, P8, P10 
M8, MY 
8 289 P 3 T3NOM0 15 (5) D A P1, P7, P18 
9 290 P 2 T3NOM0 38 (31) P A P1, PT, P8, P10, P18 
M8, M10, MY 
10 295 LM 3 T1NxM0 9 (0) D AH P8, P10 
M1, M18, MY 
320 TUR A P10 
M7, M8, M10, MY 
11 296 TUR 3 T4N2M0 13 (0) P A P8, P18 
M18 
12 341 P 1 T2NOM0 30 NP D - -  
13 342 P 1 T2NOM0 29 NP A P1, P7, P8, PI0, P18, PY 
14 343 P 2 T3NOM0 29 NP A - -  
15 352 P 2 T3NOM0 17 NP D M8 
16 354 P 3 T3NOM0 26 NP A P7, P8, P10, P18 
17 362 P 3 T4NOM0 23 (19) P A P1, P8, P18 
M18 
18 371 TUR 2 TINxM0 40 (0) D A - -  
19 382 P 1 T2NOM0 19 NP D - -  
20 389 P 2 T3NOM0 20 NP D P7, P10, P18 
M7, M10 
21 395 P 2 T3NOM0 18 NP D M18, MY 
22 400 TUR 3 T4NxM2 25 (0) D NE - -  
23 420 TUR 3 T2NxM0 13 (0) P NE P10 
M1, M10 
Abbreviations: FISH, fluorescence in situ hybridization; FCM, flow cytometry; PC, prostate carcinoma; P, primary tumor; TUR, transurethral 
resection; LM, lymph node metastasis; G, tumor grade; Nx, one or more positive lymph nodes; FU, total follow-up time in mo; NP, not 
progressed; P, progressed; D,deceased from PC; DN, deceased, not from PC; D, diploid; T, tetraploid; A, aneuploid; AH, hypodiploid aneuploid; 
NE, not evaluable; P, polysomy; M, monosomy or nullisomy. 
* Time to progression, when appropriate, in brackets. 
t P and M percentages ator above cutoff percentage for each chromosome as specified in Table 2. 
Tissue Processing and Sample Preparation 
Suspected ben ign  hyperplasia or carc inoma tissues were 
excised and cut into several smaller fragments, snap frozen 
in l iquid nitrogen,  and stored at -80°C. For isolation of cells 
f rom tissue, approximately 0.5 mL of phosphate-buf fered sa-
l ine (PBS) was added to a thawed specimen. Subsequently, 
the tissue pieces were minced with a scalpel into a suspension 
of small cell c lumps and single cells. The  clumps were dis- 
carded after sedimentat ion for 3 to 5 minutes in 5 mL of PBS. 
The supernatant  was centr i fuged, and the result ing pel let 
washed and resuspended in PBS. The cell suspension was 
incubated with hypotonic solution (0.075 mol /L  potassium 
chloride) for 10 minutes at 37°C and fixed in methano l /  
acetic acid (3:1). Fixed cells were stored in methano l  at -20°C 
unti l  used for FISH. The previously descr ibed procedure was 
adequate for tissue processing, and  fixation of nuclei  f rom 
both  primary tumor  tissue and  lymph node  metastases. As 
nuclei  f rom TUR tissue tended to coagulate in suspension, 
an addit ional  sedimentat ion step at uni t  gravity was necessary 
for these preparat ions.  
FCM Procedure 
Samples were processed for DNA-FCM as described. 3 The 
ploidy of  the dif ferent peaks in histograms from tumor  sam- 
ples was calculated f rom their  position, relative to the GO/ 
G1 peak (C = 2) in a histogram of cultured normal  diploid 
prostate fibroblasts. Diploid: C = 1.9 to 2.2; hypodiploid C 
1.8; hyperdiploid C = 2.3 to 2.7; triploid: C = 2.8 to 3.4; 
tetraploid: C = 3.5 to 4.2. Samples had a significant etraploid 
cell populat ion when the tetraploid peak, represent ing dip- 
loid G2/M as well as tetraploid tumor  G0/G1 nuclei, con- 
tained more than 10% of the nuclei. 
FISH Procedure 
The chromosome-specif ic probes used were PUC 1.77 
for chromosome 114; p7t.1 for chromosome 715; D8Z2 for 
chromosome 816; D10Z1 for chromosome 1017; L1.84 for chro- 
mosome 1818; and  DYZ5 (Amprobe; Amersham, Buckingham- 
shire, England) for the Y chromosome.  Hybridization and 
detect ion were per formed as descr ibed before. 2Hybridization 
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TABLE 2. Combined Results of FISH Analysis of Six Centromere Probes in 11 BPH Specimens 
ANC 
Loss of Signals* Extra signalst Cutoff~ 
Chromosome Mean % + SD Cutoff %~. Mean % ± SD Cutoff %~ Mean ± SD Gain Loss 
1 3.5 ± 2.4 8.3 2.1 ± 1.4 5.0 1.99 ± 0.03 2.08 1.90 
7 2.4 -+ 2.1 6.6 2.1 ± 1.0 5.0 2.00 ± 0.03 2.09 1.91 
8 3.2 + 2.5 8.2 1.8 ± 1.0 5.0 1.99 ± 0.03 2.08 1.90 
10 2.6 ± 2.2 7.0 1.8 ± 1.3 5.0 2.00 ± 0.02 2.06 1.94 
18 1.2 ± 1.1 5.0 2.2 + 1.6 5.4 2.01 ± 0.02 2.07 1.95 
Y 1.0 ± 1.3 5.0 4.4 ± 2.3 9.0 1.03 ± 0.03 1.12 0.94 
Abbreviations: ANC, average number  of  copies; FISH, fluorescence in situ hybridization; BPH, benign prostatic hyperplasia; SD, standard 
deviation. 
* Loss of signals: percentage of less than two spots for chromosomes 1, 7, 8, 10, and 18; less than one spot for Y. 
t Extra signals: percentage of greater than two spots for chromosomes 1, 7, 8, 10, and 18; greater than one spot for Y. 
++ Cutoff percentage = mean + 2 × SD; at least 5%. 
§ Cutoff ANC for gain = mean ANC + 3 × SD; cutoff ANC for loss = mean ANC - 3 × SD. 
of the biotinylated probe (15 ng per slide) to the nuclei oc- 
curred during overnight incubation at 37°C in a moist cham- 
ber in 65% formamide for chromosomes 1, 18, and Y and in 
60% formamide for chromosomes 7, 8, and 10. 
Evaluation and  Statistics 
For the evaluation of FISH signals, the authors used the 
criteria defined by Hopman et a119: (1) nuclei should be intact 
and should not overlap; and (2) FISH signals within one nu- 
cleus should be completely separated (split or paired spots 
should be counted as one) and of the same intensity. When 
these criteria could not be met, such nuclei were excluded 
from counting. When more than 10% of the nuclei on a slide 
had to be excluded, the hybridization was repeated. When 
there were more than 5% nuclei with one spot on a slide, the 
hybridization was also repeated. At least 300 nuclei were 
scored per sample and per probe. 
In mixed tumor-normal samples, small aberrations will 
not be detectable when the percentage of nontumor cells is 
too large. To compensate for this heterogeneity, only tumor 
samples that contained more than 50% tumor cells were elect- 
able for this study. So, depending on the cutoff percentage 
(range, 5% to 9%; Table 2), aberrations occurring in as few 
as 10% of the tumor cells could still be detected. 
For each chromosome in each specimen, the average 
number of copies (ANC) was calculated (total number of 
spots counted/total number of nuclei counted). Conse- 
quently, an ANC of 0.90 for Ymeans that 10% of the nuclei 
in a tissue sample show no signal; an ANC of 2.15 means that 
a maximum of 15% of the nuclei show gain of one or more 
signals. The Kruskal-Wallis test was used to test the relation 
between the ANC and clinical stage, u
scored with low frequency. Only the Y chromosome 
showed a relatively high mean (4.4%) for extra spots 
scored. Because no evidence for numerical  abnormali-  
ties of  the investigated chromosomes was shown, BPH 
could be considered a diploid control. Thus, the BPH 
results were used to assess cutoff  ANCs (Table 2). Sig- 
nificant gain and loss (further referred to as gain and 
loss) of  the investigated chromosomes in PC are de- 
f ined as at or above cutof fANC for gain and at or below 
cutoff  ANC for loss, respectively. 
PC Specimens 
Detailed data per specimen and per chromosome 
are listed in Appendix 1. Significant numerical  aberra- 
tions were detected for all six investigated chromo- 
somes. Gain (trisomy and tetrasomy combined; occa- 
sionally, pentasomy and hexasomy) was more common 
than loss (monosomy and nullisomy). Gain was highest 
for chromosome 10 (64.7%) and lowest for chromo- 
some Y (16.3%). Loss was highest for Y chromosome 
(14%) and lowest for chromosome 7 (2.6%). In meta- 
static tumors, more aberrations were detected than in 
nonmetastatic tumors. Five tumors did not show any 
abnormalities, whereas in 21 tumors one or more chro- 
mosomes howed simultaneous gain and loss. This re- 
sulted mostly in normal  values for the ANC. 
Chromosome 1 
RESULTS 
BPH Specimens 
For the 11 BPH specimens investigated, the ANCs 
for each investigated chromosome were narrowly dis- 
tr ibuted around the diploid values (Table 2). The 
ranges found were 1.93 to 2.05 (chromosome 1), 1.94 
to 2.03 (chromosome 7), 1.93 to 2.04 (chromosome 8), 
1.96 to 2.05 (chromosome 10), 1.98 to 2.05 (chromo- 
some 18), and 0.97 to 1.07 (Y chromosome) .  
Loss of  signals as well as extra spots were generally 
The results for chromosome 1 showed gain in 
37.8% but loss in less than 10% of  the tumors (Fig 1). 
Two cases (PC202 and PC302) showed simultaneous 
loss and gain. In metastatic tumors, gain was more fre- 
quent than in nonmetastatic tumors. Loss was found 
only in two metastatic tumors (PC295 and PC420). 
Polysomy was observed in all stage groups irrespective 
of  long or short survival time of the patient (Table 
1). Statistics did not  show any correlation of  numerical  
aberrations with increasing stage, metastatic disease, or 
tumor site (Table 3). 
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FIGURE 1. Percentages of gain and loss of chromosomes 1, 
7, 8, 10, 18, and Y in nonmetastatic, metastatic, and all PC 
specimens, respectively. For chromosomes 1 and 18, all investi- 
gated tumor specimens could be evaluated (ie, 15 nonmeta- 
static and 31 metastatic specimens). For chromosomes 7, 8, 
10, and Y, 14, 14, 11, and 15, respectively, nonmetastatic and 
25, 29, 24, and 29, respectively, metastatic specimens were 
evaluable. Positive percentages (standing bars) represent 
gain; negative percentages (hanging bars) represent loss. 113, 
Nonmetastatic; ~, metastatic; • all. 
Chromosome 7 
Numerical aberrations of chromosome 7 were ob- 
served in 41% of the tumors. Although only one tumor 
(PC320) showed loss, gain was observed in 38.8% of 
the tumors. Seven tumors howed simultaneous loss and 
gain. Gain of chromosome 7 was more frequent in met- 
astatic tumors, and a significant difference between the 
ANCs of nonmetastatic and metastatic tumors was 
found (Fig 1). However, high percentages of polysomy 
were observed in two patients that were disease free for 
more than 2 years (PC290 and PC342; Table 1). The 
ANCs of radical prostatectomy specimens and lymph 
node metastasis (LM) specimens were significantly dif- 
ferent (Table 3). 
Chromosome 8 
The copy number of chromosome 8 was shown to 
be aberrant in 51% of the tumors. Gain of chromosome 
8 was more frequently found in metastatic tumors, 
whereas loss occurred more often in nonmetastatic tu- 
mors (Fig 1). Seven of 10 tumors with loss also showed 
gain. Four of five LM showed high percentages of poly- 
somy (PC244, PC269, PC270, and PC295; Table 1). All 
these patients died within 2 years. However, also in one 
specimen from a patient who was disease free for more 
than 2 years (PC342), a high percentage of polysomy 
was found. High percentages of monosomy were ob- 
served in two lymph node-posit ive T3 tumors (PC256 
and PC352). Significant differences in ANC values were 
found between nonmetastafic and metastatic tumors 
(Fig 1), between radical prostatectomy and TUR speci- 
mens, and between radical prostatectomy and LM speci- 
mens (Table 3). 
Chromosome 10 
Gain of chromosome 10, the most frequently 
found numerical aberration (64.7% of the tumors) cot- 
related with metastatic disease (Fig 1). Significant loss 
of chromosome 10 occurred in only one metastatic tu- 
mor (PC479). However, concurrent loss and gain of 
chromosome 10 was found in another 10 tumors. ANC 
values tended to increase with stage (P = .05) but 
showed no relation to the survival time. The ANCs of 
LM were significantly higher than those of radical pros- 
tatectomy specimens but were not different from TUR 
values (Table 3). 
Chromosome 18 
Gain and loss of chromosome 18 were about 
equally frequent in nonmetastatic and in metastatic tu- 
mors (Fig 1). High polysomy percentages were present 
in all stage groups, the highest values being found in 
patients with short survival (eg, PC269, PC270, and 
PC291; Table 1). Statistics did not reveal any correlation 
of numerical aberrations with tumor site (Table 3). 
Y Chromosome 
Aberrations of Y chromosome, qually divided be- 
tween loss and gain, did not correlate with any clinical 
parameter (Table 3), although the frequency of loss 
was higher in metastatic tumors (Fig 1). Only two cases 
showed simultaneous loss and gain (PC290 and PC332). 
The mean age of PC patients with a tumor that showed 
loss of Y chromosome was 65.4 + 13.2 (range, 54 to 
86 years; N = 7). The mean age of patients without 
chromosome Y loss was 67.0 + 10.2 (range, 49 to 93 
years; N = 36). 
DNA-FCM Compared With FISH Results of 
PC Patients With Follow-Up and Staging 
Data 
Of the 24 specimens, investigated both by FISH 
analysis and DNA-FCM, seven tumors were DNA dip- 
loid, three were tetraploid, and 14 were aneuploid (Ta- 
ble 1). Six of seven DNA diploid tumors occurred in 
node-negative patients, whereas the three tetraploid tu- 
mors were all from node-positive patients. Aneuploid 
TABLE 3. Correlations of ANC Values per 
Chromosome With Tumor Site 
P Values* 
Chromosome RP/TURt  RP/LM~ TUR/LM§ 
1 .81 .41 .24 
7 .O9 .04 .29 
8 .03 .04 .12 
10 .08 .03 .26 
18 .91 .22 .34 
Y .48 .54 .39 
Abbreviations: ANC, average number  of copies; RP, radical pros- 
tatectomy; TUR, transurethral resection; LM, lymph node metastasis. 
* Kruskal-Wallis test; Pvalues in bold typeface indicate statistical 
significance. 
+ RP vs TUR. 
+ RP vs LM. 
§ TUR versus LM. 
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tumors were found in patients that were at least node 
positive or staged T3, except case no. 13 (T2N0). Inves- 
tigated with FISH, five tumors did not show any numeri- 
cal aberration. Two of these tumors were diploid 
(PC341 and PC382), and two were aneuploid (PC343 
and PC371). The fifth (PC400) was not evaluable by 
FCM. All other tumors showed numerical aberrations 
of one or more chromosomes. The average number  of 
aberrant chromosomes in diploid tumors was 2.0 + 2.2, 
and in aneuploid and tetraploid tumors together was 
4.7 + 2.3. Chromosome gain was most prominent in 
highly DNA aneuploid tumors (PC244, PC269, PC270, 
PC290, PC291, PC295, PC342, and PC354). Tumors 
with hypodiploid cell populations could show chromo- 
some loss (PC295), or not (PC269). However, some 
tumors that did not show hypodiploid cells with FCM 
(eg, PC202, PC256, and PC290) showed loss for more 
than one chromosome. 
Cases With Multiple Specimens 
PC256 and PC384 (case no. 4) showed a DNA histo- 
gram with about the same percentage of tetraploid cells 
(Fig 2). FISH showed numerical aberrations for all in- 
vestigated chromosomes in both specimens, but loss of 
chromosome 7 and gain of chromosome 10 were more 
pronounced in the second sample PC384. 
The two samples obtained from case no. 5 (PC269 
and PC291) displayed a profound dissimilarity in FCM 
results, with different proportions of different DNA 
content (Fig 2). With FISH, all investigated chromo- 
somes showed numerical aberrations in both samples. 
Although polysomy of chromosomes 1, 8, and especially 
18 was far more extended in PC291, in PC269 chromo- 
some 10 was more polysomic than in the second sample. 
The two samples obtained from case no. 10 were 
also heterogeneous with respect o FCM results. In the 
TUR (PC320, sample contained 80% tumor cells), a 
triploid stemline (3.0C) was found, whereas in a sample 
from the xenografted cell line (PC295), which conse- 
quently consisted exclusively of tumor cells, a hypotetra- 
ploid (3.7C) and a hypodiploid stemline (1.4C) were 
observed (Fig 2). The histograms of the FISH results 
showed, however, that these tumors were clearly re- 
lated: Both samples howed polysomy for chromosomes 
8 and 10, and loss for more than one chromosome. 
Losses were more extensive in PC295 than in PC320, 
except for Y chromosome, which was completely lost in 
PC320 and only partly lost in PC295. 
DISCUSSION 
In the BPH samples tested, essentially no numeri- 
cal aberrations were detected for the six chromosomes 
investigated. These results are in contrast with the re- 
port of Aly et al, 2° who found loss of chromosome Y 
and gain of chromosome 7 in several cultured BPH 
specimens. Based on the findings in the present study, 
the authors assumed that occasional BPH cells would 
not Contribute to any chromosomal abnormalities 
found in PC specimens. 
DNA-FCM studies on about one half of the tumors 
showed that the frequency of DNA aneuploidy in- 
creased with increasing tumor stage. Combined FISH 
and DNA-FCM showed that, as expected, most aneu- 
ploid tumors had numerical chromosomal berrations. 
It was, however, also shown that most diploid tumors 
also had one or more numerically aberrant chromo- 
somes. This can be explained by the fact that only chro- 
mosomal aberrations that constitute more than 4% of 
the total amount of DNA can be detected with DNA- 
FCM. No chromosome seemed to be specifically aber- 
rant in DNA diploid tumors. 
Forty-one of 46 PCs showed numerical aberrations 
of one or more chromosomes of the six chromosome 
panel. All investigated chromosomes individually 
showed numerical aberrations in at least 30% of the 
specimens, and gain was more frequent han loss. Gain 
of chromosome 10 was the most frequent numerical 
aberration found (65%); chromosome 8 was the second 
most frequently gained chromosome (44%); and chro- 
mosomes 1, 7, and 18 showed gain with a frequency 
between 35% and 40%. The Y chromosome showed 
the lowest frequency of gain (16%), but the highest 
frequency of loss (14%). Gain of chromosomes 7, 8, 
and 10 correlated with metastatic disease. Moreover, 
the ANC of chromosome 10 was significantly higher in 
advanced tumors. Gain of chromosome 10 in PC has 
been reported before, l° and deletions of part of 10q 
have been reported in cytogenetic ~'21 and loss ofhetero- 
10 22~24 zygosity (LOH) studies. ' " However, the association 
of chromosome 10 aberrations with metastatic disease 
is a new finding. 
In a previous tudy, the authors of the present study 
were the first to suggest hat 8p deletions are possibly 
important aberrations in PC. 25 Since then, 8p deletions 
have been reported in several cytogenetic studies of 
PCs. 1'10'26-28 Recently, the importance of loss of chromo- 
some 8p sequences in PC and the putative presence of 
at least two tumor suppressor genes on chromosome 8p 
has been established by several LOH studies.  26-31 The de- 
letions that were found by LOH mapping often spanned 
most of the 8p arm and sometimes involved the centro- 
merle region. In the present study, loss of chromosome 
8 was seen primarily in nonmetastatic tumors, whereas 
in metastatic tumors gain was more prominent. 
Deletions of 7q are among the first aberrations re- 
ported in PC. ~ Gain of chromosome 7 has been found in 
cytogenetic 5'21'22"a2 nd FISH studies. 1°'11'33'34 In agreement 
with the findings in the present study, Bandyk et  a111 
observed that gain of chromosome 7 was significantly in- 
creased in PC metastases compared with primary tumors. 
Loss of chromosomes 7, 8, and 10 was observed 
mostly simultaneously with gain in the same tumor sam- 
ples, which is suggestive for heterogeneity in such tu- 
mors. In fact, chromosome 8 centromere gains and 
losses were shown to exist in different areas of the same 
tumors. 5 Loss of (part of) a homologue followed by 
multiplication of the other homologue is one possible 
mechanism through which these numerical aberrations 
could be generated. Another mechanism could be the 
formation of an isochromosome, followed by a nondis- 
junction event. This has been suggested as an explana- 
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F IGURE 2 .  FISH and DNA-FCM results of  cases with mult iple specimens.  (A and  B) Case  no, 4. (C  and  D)  Case no. 5. (E and  F) 
Case  no. 10. • 1; [ ]  7; [ ]  8; • 10; [ ]  18; [ ]  Y. 
tion for the simultaneous loss of 8p and gain of 8q. 27 
In a recent comparative genome hybridization study of 
PC, it was reported that loss of 8p and gain of 8q occur 
frequently, but that gain of (the whole) 7 and loss of 
10q are infrequent observations. 35 
Chromosome 18 likewise showed simultaneous loss 
and gain in most tumors, suggesting similar possible 
mechanisms as stated previously. The percentage of nu- 
merical aberrations of chromosome 18, however, did 
not correlate with metastatic disease. Moreover, the au- 
thors have reported before that DNA diploid PCs, which 
mostly are early] tumors, often already show gain of 
2 chromosome 18. " So numerical aberrations of chromo- 
some 18 are likely to be an early event in PC. In fact, 
recently allelic losses of 18q were reported in six of 20 
early-stage PCs. ~6 It will be of interest o investigate if
chromosome 18 aberrations are already present in the 
preneoplastic prostatic intraepithelial neoplasia lesions. 
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Aberrations of both chromosomes 1 and Y also did 
not correlate with metastatic disease. Furthermore, si- 
multaneous loss and gain were only rarely observed. 
Previously, the authors 2 described that gain of chromo- 
somes 1 and Ywas largely restricted to DNA aneuploid 
tumors, and this finding was confirmed in the present 
study. Y loss in the tumor did not correlate with the 
patients age. So alternative mechanisms, like multiplica- 
tion through tetraploidization of the whole genome 37 
or loss of Yas a reflection of a general state of hyperpro- 
liferation, 3s are more likely explanations for the aberra- 
tions found for these chromosomes. 
Comparison of two consecutive samples from the 
same patients revealed similar results with FCM in only 
one of three cases. However, FISH analysis of these 
specimens revealed clear evidence of karyotypic evolu- 
tion toward a more aberrant karyotype. 
The present article has substantiated the value of 
centromere FISH as a means to look at the ploidy of 
individual chromosomes in prostate cancer tissue. Nu- 
merical aberrations were found for all six investigated 
chromosomes; no doubt, most other chromosomes, 
when eventually investigated, will also show numerical 
aberrations in at least part of the PCs. The most im- 
portant finding was, however, that combined with clini- 
cal data, gains of chromosomes 7, 8, and 10 were shown 
to be definitely involved in the progression of PC. This 
not only substantiates the postulated presence of tumor 
suppressor genes on 8p but also justifies renewed inter- 
est in the commonly deleted regions on 7q and 10% 1 
APPENDIX 1. Average Number  of Copies of Investigated Chromosomes per Tumor Sample 
PC NR ANC 1 ANC 7 ANC 8 ANC 10 ANC 18 ANC Y 
Nonmetastatic umors 
256j" 2.05 1.95 1.92" 2.01" 2.02* 1.02 
285 2.08 2.01 NE NE 2.11 1.06 
288 2.11 2.00 1.95' 2.17 1.99 0.94 
290 2.49 2.46 2.31" 2.16" 2.26 1.02" 
341+  1.96 2.02 1.99 1.99 1.97 1.01 
342 2.32 2.38 2.51 2.12 2.17 1.22 
3435 1.93 1.99 1.97 2.00 1.98 0.97 
352 1.97 2.01 1.90 NE 1.96 1.01 
354 2.03 2.14 2.09 2.11 2,35 1.02 
362 2.29 2.02 2.11 2.05 2.03* 1.06 
382 2.01 2.05 1.95 2.00 2.01 1.03 
389 2.05 2-02* 2.00 2.09* 2.12 1.08 
395 1.95 1.93 2.03 1.97 1.94 0.91 
432 1.96 1.98 1.79 NE 1.99 1.01 
435++ 2.04 NE 2.02 NE 2.04 1.09 
Metastatic Tumors 
202 2.03* 2.07" 1.98" 1.95" 2.08 0.97 
236 2.04 2.06 2.02 2.12 1.99 1.01 
244 2.03 2.37 2.31 2.34 2.35 0.98 
262 2.06 2.08 NE 2.02* 1.97 NE 
2691" 2.24 2,17 2.24 2.30 2.40 1.11 
270 2.30 2.28 2.80 2.44 2.36 1.26 
289 2.28 2,12 1.91 2.03 2.29 1.06 
291 t 2.42 2.17 2.30 2.08* 2.53 1.02 
295 t 1.80 NE 2.60 2.71 1.64 0.72 
296 2.01 2,06 2.11 NE 2.02* 1.05 
302 2.06* 2.03* 2.11 2.21" 2.17 0.99 
320 t 1.97 1.90 2.04* 2.11" 1.93 0 
324 2.04 2.08 2.03 2.11 1.94 0.21 
332 2.07 NE 1.99" NE 1.98 1.05" 
351 2.20 2.52 2.34 2.51 2.12 1.11 
353 2.09 2.28 NE 2.36 1.99* NE 
355 2.37 2.09* 2.12" 2.10 2.29 1.03 
366 2.28 2.35 2.13 2.23 2.14" 0.79 
371 + 2.00 2.04 1.99 2.03 2.00 0.98 
384]" 2.16 1.97" 2.13 2.23 2.12 0.97 
392 2.00 2.07 2.00* NE 2.01 1.01 
400++ 1.94 2.06 1.95 NE 2.01 1.02 
403 1.96 2.01" 2.07 2.03* 1.98 1.08 
405 2.04 NE 2.09 NE 1.98 1.15 
417 1.95 NE 2.17 NE 2.05 1.02 
418 2.03 2.48 2.27 2.21 2.49 1.03 
420 1.90 NE 2.06 2.14" 1.98 1.00 
449 2.18 2.21 2.09 NE 2.03* 1.27 
461 2.01 NE 2.03 2.06 2.01 0.92 
465 2.26 2.18 2.33 2.14 2.18" 1.23 
479 1.96 1.98" 1.89 1.85 1.90 1.00 
Abbreviations: NE, not evaluable; PC, prostate carcinoma; NR, number; ANC, average number of copies; bold 
loss. 
* Simultaneous significant gain and loss. 
Specimen from double-sampled patient. 
Specimen without chromosomal berrations. 
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